ISAL 2019 | Targeted therapy for AML: current outlook and future potential

Name: Targeted therapy for AML: current outlook and future potential
Uploaded: 2019-02-24T00:00:00.000Z
Duration: 3 min 27 s
Description: Speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, Lars Bullinger, MD, of Charité University of Medicine, Berlin, Germany, talks to us about the current landscape and future role for targeted therapies in acute myeloid leukemia (AML).

Lars Bullinger • 24 Feb 2019

ISAL 2019

Acute Myeloid Leukemia Leukemia Midostaurin

Speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, Lars Bullinger, MD, of Charité University of Medicine, Berlin, Germany, talks to us about the current landscape and future role for targeted therapies in acute myeloid leukemia (AML).